Abbott filed agreements to issue $20 billion in senior notes to help finance its pending $23 billion acquisition of Exact Sciences. The multi‑maturity offering ranges from floating‑rate notes due 2029 to long‑dated fixed‑rate notes maturing in 2066; underwriters include Morgan Stanley and JPMorgan. Abbott said proceeds will also be used to repay certain Exact Sciences indebtedness and for general corporate purposes. The financing step comes after Exact shareholders approved the purchase and signals Abbott’s commitment to closing in the second quarter of 2026. The scale and tenor of the debt package reflect market appetite for large‑cap pharma M&A financing but will be scrutinized for leverage implications and integration risk.